Design, synthesis, and structural analysis of phenylpropanoic acid-type PPARγ-selective agonists: Discovery of reversed stereochemistry-activity relationship

Journal of Medicinal Chemistry

Volumn 54, Issue 1, 2011, Pages 331-341

  Ohashi, Masao ^a   Oyama, Takuji ^b   Nakagome, Izumi ^c   Satoh, Mayumi ^d   Nishio, Yoshino ^a   Nobusada, Hiromi ^a   Hirono, Shuichi ^c   Morikawa, Kosuke ^b   Hashimoto, Yuichi ^e   Miyachi, Hiroyuki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^e UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZYL 3 [3 (((4 ADAMANTAN 1 YL)BENZAMIDO)METHYL) 4 PROPOXYPHENYL]PROPANOIC ACID; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY;

BINDING SITES; DRUG DESIGN; HEK293 CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHENYLPROPIONATES; PPAR GAMMA; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTIONAL ACTIVATION;

EID: 78651111373     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101233f     Document Type: Article

References (33)

1. Chawla, A.; Repa, J. J.; Evans, R. M.; Mangelsdorf, D. J. Nuclear receptors and lipid physiology: opening the X-files Science 2001, 294, 1866-1870
2. Banner, C. D.; Göttlicher, M.; Widmark, E.; Sjövall, J.; Rafter, J. J.; Gustafsson, J. A. Systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptors from biological extracts: characterization of peroxisome proliferator-activated receptor activators in plasma J. Lipid Res. 1993, 34, 1583-1591
3. Braissant, O.; Foufelle, F.; Scotto, C.; Dauca, M.; Wahli, W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat Endocrinology. 1996, 137, 354-366
4. Spiegelman, B. M.; Hu, E.; Kim, J. B.; Brun, R. PPAR gamma and the control of adipogenesis Biochimie 1997, 79, 111-112
5. Okuno, A.; Tamemoto, H.; Tobe, K.; Ueki, K.; Mori, Y.; Iwamoto, K.; Umesono, K.; Akanuma, Y.; Fujiwara, T.; Horikoshi, H.; Yazaki, Y.; Kadowaki, T. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats J. Clin. Invest. 1998, 101, 1354-1361
6. Mendez, M.; LaPointe, M. C. PPARgamma inhibition of cyclooxygenase-2, PGE2 synthase, and inducible nitric oxide synthase in cardiac myocytes Hypertension 2003, 42, 844-850
7. Morrison, R. F.; Farmer, S. R. Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis J. Biol. Chem. 1999, 274, 17088-17097
8. Huang, J. W.; Shiau, C. W.; Yang, J.; Wang, D. S.; Chiu, H. C.; Chen, C. Y.; Chen, C. S. Development of small-molecule cyclin D1-ablative agents J. Med. Chem. 2006, 49, 4684-4689
9. Chaplain, M. A.; McDougall, S. R.; Anderson, A. R. Mathematical modeling of tumor-induced angiogenesis Annu. Rev. Biomed. Eng. 2006, 8, 233-257
10. Sato, M. Peroxisome proliferator activated receptor ligands and angiogenesis Nippon Rinsho 2005, 63, 603-608
11. Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T. M.; Kliewer, S. A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J. Biol. Chem. 1995, 270, 12953-12956
12. Hashimoto, Y.; Miyachi, H. Nuclear receptor antagonists designed based on the helix-folding inhibition hypothesis Bioorg. Med. Chem. 2005, 13, 5080-5093
13. Nomura, M.; Tanase, T.; Ide, T.; Tsunoda, M.; Suzuki, M.; Uchiki, H.; Murakami, K.; Miyachi, H. Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor activators; discovery of potent and human PPARα subtype-selective activators J. Med. Chem. 2003, 46, 3581-3599
14. Kasuga, J.; Yamasaki, D.; Araya, Y.; Nakagawa, A.; Makishima, M.; Doi, T.; Hashimoto, Y.; Miyachi, H. Design, synthesis and evaluation of a novel series of α-substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor (PPAR) alpha/delta dual agonists for the treatment of metabolic syndrome Bioorg. Med. Chem. 2006, 14, 8405-8414
15. Kasuga, J.; Nakagome, I.; Aoyama, A.; Sako, K.; Ishizawa, M.; Ogura, M.; Makishima, M.; Hirono, S.; Hashimoto, Y.; Miyachi, H. Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists Bioorg. Med. Chem. 2007, 15, 5177-5190
16. Kasuga, J.; Yamasaki, D.; Ogura, K.; Shimizu, M.; Sato, M.; Makishima, M.; Doi, T.; Hashimoto, Y.; Miyachi, H. SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail Bioorg. Med. Chem. Lett. 2008, 18, 1110-1105
17. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.; Oplinger, J. A.; Kliewer, S. A.; Gampe, R. T., Jr.; McKee, D. D.; Moore, J. T.; Willson, T. M. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 13919-13924
18. Evans, D. A.; Ennis, M. D.; Mathre, D. J. Asymmetric alkylation reactions of chiral imide enolates. A practical approach to the enantioselective synthesis of alpha-substituted carboxylic acid derivatives J. Am. Chem. Soc. 1982, 104, 1737-1739
19. The enantiomeric excess was determined with a CHIRALPAK AD-H column, with hexane/ i -PrOH/trifluoroacetic acid = 90:10:0.1 v/v/v as the mobile phase, at a flow rate of 0.5 mL/min, with detection at 254 nm.
20. Sznaidman, M. L.; Haffner, C. D.; Maloney, P. R.; Fivush, A.; Chao, E.; Goreham, D.; Sierra, M. L.; LeGrumelec, C.; Xu, H. E.; Montana, V. G.; Lambert, M. H.; Willson, T. M.; Oliver, W. R., Jr.; Sternbach, D. D. Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta); synthesis and biological activity Bioorg. Med. Chem. Lett. 2003, 13, 1517-1521
21. Cobb, J. E.; Blanchard, S. G.; Boswell, E. G.; Brown, K. K.; Charifson, P. S.; Cooper, J. P.; Collins, J. L.; Dezube, M.; Henke, B. R.; Hull-Ryde, E. A.; Lake, D. H.; Lenhard, J. M.; Oliver, W., Jr.; Oplinger, J.; Pentti, M.; Parks, D. J.; Plunket, K. D.; Tong, W. Q. N -(2-Benzoylphenyl)- l -tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N -aryl substituent J. Med. Chem. 1998, 41, 5055-5069
22. Hulin, B.; Newton, L. S.; Lewis, D. M.; Genereux, P. E.; Gibbs, E. M.; Clark, D. A. Hypoglycemic activity of a series of alpha-alkylthio and alpha-alkoxy carboxylic acids related to ciglitazone J. Med. Chem. 1996, 39, 3897-3907
23. Oyama, T.; Toyota, K.; Waku, T; Hirakawa, Y.; Nagasawa, N.; Kasuga, J.; Hashimoto, Y.; Miyachi, H.; Morikawa, K. Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures Acta Crystallogr., Sect. D: Biol. Crystallogr. 2009, 65, 786-795
24. Computer-graphic work was performed using MOE (Molecular Operating Environment) (Ryoka Systems Inc.).
25. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H; Kurokawa, R.; Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-gamma Nature 1998, 395, 137-143
26. Rosenfeld, M. G.; Lunyak, V. V.; Glass, C. K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response Genes Dev. 2006, 20, 1405-1428
27. Nagy, L.; Kao, H. Y.; Love, J. D.; Li, C.; Banayo, E.; Gooch, J. T.; Krishna, V.; Chatterjee, K.; Evans, R. M.; Schwabe, J. W. Mechanism of corepressor binding and release from nuclear hormone receptors Genes Dev. 1999, 13, 3209-3216
28. Ogston, A. G. Interpretation of experiments on metabolic processes, using isotopic tracer elements Nature 1948, 163, 963
29. Easson, L. H.; Stedman, E. Studies on the relationship between chemical constitution and physiological action-Molecular dissymmetry and physiological activity Biochem. J. 1933, 27, 1257-1266
30. Waku, T.; Shiraki, T.; Oyama, T.; Fujimoto, Y.; Maebara, K.; Kamiya, N.; Jingami, H.; Morikawa, K. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids J. Mol. Biol. 2009, 385, 188-199
31. Otwinowski, Z.; Minor, W. Methods Enzymol. 1997, 276, 307-326
32. Brünger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular structure determination Acta Crystallogr. 1998, D54, 905-921
33. Jones, T. A.; Zou, J.-Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models Acta Crystallogr. 1991, A47, 110-119